PhaseRx, Inc. (PZRX) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS

PhaseRx, Inc. (NASDAQ:PZRX) released its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.09, Bloomberg Earnings reports.

Shares of PhaseRx (NASDAQ:PZRX) opened at 0.6869 on Friday. PhaseRx has a 12-month low of $0.01 and a 12-month high of $3.58. The company has a 50-day moving average of $0.82 and a 200 day moving average of $1.23. The stock’s market capitalization is $8.03 million.

COPYRIGHT VIOLATION NOTICE: “PhaseRx, Inc. (PZRX) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/12/phaserx-inc-pzrx-issues-quarterly-earnings-results-misses-expectations-by-0-09-eps.html.

A hedge fund recently raised its stake in PhaseRx stock. Vanguard Group Inc. increased its position in shares of PhaseRx, Inc. (NASDAQ:PZRX) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,182 shares of the company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.22% of PhaseRx worth $135,000 at the end of the most recent reporting period. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Separately, ValuEngine lowered shares of PhaseRx from a “sell” rating to a “strong sell” rating in a report on Friday, May 19th.

About PhaseRx

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

What are top analysts saying about PhaseRx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhaseRx Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit